MA-EVERBRIDGE
25.1.2021 13:32:08 CET | Business Wire | Press release
Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced COVID-19 Shield™: Vaccine Distribution , an extension to its CEM platform offering risk insights, logistics awareness and vaccine appointment management to support the full spectrum of organizations that develop, manufacture, transport, distribute, regulate, and administer the coronavirus vaccine. The offering also provides governments with a single, unified platform to expedite vaccine coordination, communication and distribution for all residents, including vulnerable populations with special needs. Representing significant adoption for its vaccine distribution software, Everbridge announced the deployment of its CEM Platform to power the digital vaccination distribution system for a variety of municipalities and organizations, including the entire state population of West Virginia , and the County of Sarasota, Florida , among others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005258/en/
“We have partnered with Everbridge,” said Governor Jim Justice of West Virginia in a recent press conference for state residents. “Everbridge helps states notify their citizens when there’s a fire, a flood, or a hurricane, but now they are going to help us coordinate vaccines as we can get them from the federal government. We will be the first state to turn on this new vaccine scheduling system. Everbridge helped us stand this up in one week’s time.”
In the U.S., healthcare experts have stated : “at a pace of one million doses a day, the virus wouldn’t be contained until sometime in 2022.” A recent survey also reveals that 6 in 10 Americans do not know when or where to get the vaccine. In addition, the logistics of moving this type of vaccine across the country in a short period of time creates a substantial challenge , especially given the cruciality of cold chain monitoring .
Added Gov. Justice, “This system [provides residents] the ability to put your information in directly and helps us coordinate when vaccines are available to notify you when and where to come to get your vaccine. You will get a message back after you’ve registered to confirm that you are in the system and we will send you updates regularly. The system sends emails, texts, and phone calls. Whatever way you want us to notify you about your availability, [Everbridge] will let you pick up on just that.”
“During a pandemic, efficient, expeditious and equitable distribution and administration of [the] approved vaccine is critical,” as stated by the U.S. Centers for Disease Control and Prevention (CDC) in their recent guidelines . Everbridge’s new COVID-19 Shield™: Vaccine Distribution software offers federal, state and local governments as well as businesses and healthcare systems new capabilities to: better manage vaccine supply chains amidst other concurrent critical events, analyze risk of virus spread, avoid operational disruptions, and ensure the smooth rollout of vaccines to employees and citizens with easy-to-deploy software integrations.
For governments, Everbridge enables state, city and county leaders to rapidly coordinate communication across the population, automate appointment signup and monitor registrations, track vaccine availability, ensure doses are shipped to proper facilities to avoid spoilage, and enable citizen scheduling to avoid long waits and call center challenges.
Demonstrating the extreme pent up demand and need for technology to assist in the communications, scheduling and distribution of the vaccine, the County of Sarasota, Florida leveraged Everbridge’s vaccine distribution software to enable 50,000 residents to sign up for the COVID-19 vaccine in the first hour of launch, which has been reported as ‘a giant leap forward.’ “We are utilizing Everbridge to coordinate the vaccine distribution in our community,” said Rich Collins, Director of Sarasota County Emergency Services. “The system aids in tracking and prioritizing this process, which allows us to serve our vulnerable populations and frontline workers.”
“We applaud Governor Justice and the state of West Virginia for their leadership in applying best practices to help keep their citizens safer and accurately informed through effective vaccine distribution. Solving this public health crisis faster will unlock the ability for governments to fully re-open economies for the betterment of all states, people and businesses,” said David Meredith, CEO of Everbridge. “The expansion of the Everbridge critical event management software platform to include vaccine distribution creates new ways for government, healthcare and all types of businesses to automate logistics, maintain vital communications and keep people safe during this crucial rollout.”
With Everbridge’s COVID-19 Shield™: Vaccine Distribution, enterprise customers gain capabilities to: coordinate the number of employees who have been vaccinated, manage population density and access to office buildings based on vaccination status, and receive timely alerts when employees report signs of illness so they can quickly respond to safeguard staff and visitors.
“Garnet Healthcare is providing mobile COVID testing and care across Vermont, New York, and Massachusetts,” said Ryan Ferris, CEO & Co-founder at Garnet Healthcare , which provides patient logistics, care coordination, and clinical diagnostics to healthcare institutions, corporate clients, and governmental agencies across New England. “Everbridge’s CEM Platform provides situational awareness of threats to our clinical logistics which could inhibit or delay these critical services. In addition, the platform provides coordination support to help us manage the testing process and follow-up with patients supporting our end-to-end clinical services.”
The new Everbridge COVID-19 Shield™: Vaccine Distribution software solution includes the following features among the suite’s broader CEM capabilities:
- Enhanced COVID-19 Risk Feed showcasing vital real-time information, including the incidence of new virus strains and vaccine related intelligence;
- Crisis Management Module to follow, log and audit the transport, handling, and/or administration of the vaccine;
- Vaccine Distribution Logistics Service to provide situational awareness to better manage vaccine supply chains;
- Customized Employee Surveys to help confirm whether employees have received the vaccine;
- Appointment Management Tool to help manage the scheduling, tracking and communications of vaccine administration; and
- Out-of-Box Workflows in Smart Orchestration to help improve distribution management, such as vaccine appointment follow-ups.
“Everbridge helps to bridge the gap between the public sector and the private sector,” said Mark Aprigliano, Senior Director, Public Safety at Jackson Health System . “Their CEM Platform provides situational awareness of threats to the supply chain for the vaccine which could inhibit or delay distribution. It also provides a common operating picture to all of the stakeholders in that supply chain, providing visibility and a coordinated effort from manufacturing to point of vaccination.”
To learn more best practices for distribution and management of the vaccine rollout, join Everbridge and Dr. Scott Gottlieb, former U.S. Food & Drug Administration Commissioner for a discussion entitled “The End of the Pandemic: Successful Vaccine Distribution ” on Wednesday, January 27, 2021 at 11:30 a.m. ET.
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,400 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 20 cities around the globe. For more information visit www.everbridge.com
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005258/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
